RhAPPcast: Switch, Don’t Cycle: Interpreting the SELECT-SWITCH Trial and What It Means for RA Care

Stay up to date with the latest advances in rheumatoid arthritis management in this RhAPPcast Fireside Chat episode focused on the SELECT-SWITCH trial and its implications for clinical practice. Hosted by Amanda Mixon, PA-C, this discussion features expert perspectives from Jeannette Hart, PA-C, and James Levine, DO, as they explore treatment decision-making after TNF inhibitor failure and what the latest evidence means for patients with rheumatoid arthritis.

Learn why the SELECT-SWITCH trial was designed, how it compares switching to a different mechanism of action versus cycling within the TNF inhibitor class, and what the study revealed about efficacy, remission rates, and low disease activity outcomes. The panel discusses real-world considerations when selecting next-line therapies, including the role of JAK inhibitors such as upadacitinib, patient characteristics that may influence treatment choices, and how current guidelines support switching mechanisms after inadequate TNF inhibitor response.

Whether you're a rheumatology provider, advanced practice provider (APP), or healthcare professional managing patients with rheumatoid arthritis, this episode provides practical insights into interpreting clinical trial data, discussing treatment changes with patients, and balancing efficacy and safety when making therapeutic decisions. For more expert-led education, visit the Content Rheum and stay up to date with the latest clinical insights in rheumatologic care.